

UNITED STATES JUDICIAL PANEL  
on  
MULTIDISTRICT LITIGATION

IN RE: VALSARTAN, LOSARTAN, AND  
IRBESARTAN PRODUCTS LIABILITY  
LITIGATION

MDL No. 2875

(SEE ATTACHED SCHEDULE)

CONDITIONAL TRANSFER ORDER (CTO -31)

On February 14, 2019, the Panel transferred 5 civil action(s) to the United States District Court for the District of New Jersey for coordinated or consolidated pretrial proceedings pursuant to 28 U.S.C. § 1407. *See* 363 F.Supp.3d 1378 (J.P.M.L. 2019); *see* also Transfer Order, Doc. No. 401 (J.P.M.L. Dec. 18, 2019) (order on scope of MDL No. 2875). Since that time, 65 additional action(s) have been transferred to the District of New Jersey. With the consent of that court, all such actions have been assigned to the Honorable Robert B. Kugler.


It appears that the action(s) on this conditional transfer order involve questions of fact that are common to the actions previously transferred to the District of New Jersey and assigned to Judge Kugler.

Pursuant to Rule 7.1 of the Rules of Procedure of the United States Judicial Panel on Multidistrict Litigation, the action(s) on the attached schedule are transferred under 28 U.S.C. § 1407 to the District of New Jersey for the reasons stated in the order of February 14, 2019, and, with the consent of that court, assigned to the Honorable Robert B. Kugler.

This order does not become effective until it is filed in the Office of the Clerk of the United States District Court for the District of New Jersey. The transmittal of this order to said Clerk shall be stayed 7 days from the entry thereof. If any party files a notice of opposition with the Clerk of the Panel within this 7-day period, the stay will be continued until further order of the Panel.

Inasmuch as no objection is pending at this time, the stay is lifted.  
Sep 02, 2020  
CLERK'S OFFICE  
UNITED STATES  
JUDICIAL PANEL ON  
MULTIDISTRICT LITIGATION

FOR THE PANEL:



John W. Nichols  
Clerk of the Panel



TRUE AND CERTIFIED COPY

9:56 am, Sep 02 2020

**IN RE: VALSARTAN, LOSARTAN, AND  
IRBESARTAN PRODUCTS LIABILITY  
LITIGATION**

MDL No. 2875

**SCHEDULE CTO-31 – TAG-ALONG ACTIONS**

<u>DIST</u>	<u>DIV.</u>	<u>C.A.NO.</u>	<u>CASE CAPTION</u>
ALABAMA MIDDLE			
<del>ALM</del>	3	20-00609	<del>Harris v. Aurobindo Pharma USA, Inc. et al</del> Opposed 8/27/20
ALABAMA NORTHERN			
<del>ALN</del>	7	20-01216	<del>Brown v. Camber Pharmaceuticals Inc et al</del> Opposed 8/27/20
ALABAMA SOUTHERN			
<del>ALS</del>	2	20-00416	<del>Smiley v. Aurobindo Pharma USA, Inc. et al</del> Opposed 8/27/20
CALIFORNIA CENTRAL			
CAC	2	20-07535	Richard Allen Williams et al v. Zhejiang Huahai Pharmaceutical Co., Ltd., et al
ILLINOIS SOUTHERN			
ILS	3	20-00793	Maxton et al v. Prinston Pharmaceutical Inc. et al
LOUISIANA EASTERN			
LAE	2	20-02279	Craigie v. CVS Pharmacy, Inc. et al